Literature DB >> 24657655

RUNX2 is overexpressed in melanoma cells and mediates their migration and invasion.

Rajeev K Boregowda1, Oyenike O Olabisi1, Walid Abushahba1, Byeong-Seon Jeong2, Keneshia K Haenssen2, Wenjin Chen3, Marina Chekmareva4, Ahmed Lasfar5, David J Foran3, James S Goydos2, Karine A Cohen-Solal6.   

Abstract

In the present study, we investigated the role of the transcription factor RUNX2 in melanomagenesis. We demonstrated that the expression of transcriptionally active RUNX2 was increased in melanoma cell lines as compared with human melanocytes. Using a melanoma tissue microarray, we showed that RUNX2 levels were higher in melanoma cells as compared with nevic melanocytes. RUNX2 knockdown in melanoma cell lines significantly decreased Focal Adhesion Kinase expression, and inhibited their cell growth, migration and invasion ability. Finally, the pro-hormone cholecalciferol reduced RUNX2 transcriptional activity and decreased migration of melanoma cells, further suggesting a role of RUNX2 in melanoma cell migration.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cholecalciferol (Vitamin D3); FAK; Melanoma; Migration; RUNX2; Transcription factor

Mesh：

Substances：

Year:  2014        PMID： 24657655      PMCID： PMC4041161          DOI： 10.1016/j.canlet.2014.03.011

Source DB:  PubMed          Journal:  Cancer Lett        ISSN： 0304-3835            Impact factor:   8.679


  55 in total

Review 1.  Melanoma: from mutations to medicine.

Authors:  Hensin Tsao; Lynda Chin; Levi A Garraway; David E Fisher
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

2.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

Authors:  Paul B Chapman; Axel Hauschild; Caroline Robert; John B Haanen; Paolo Ascierto; James Larkin; Reinhard Dummer; Claus Garbe; Alessandro Testori; Michele Maio; David Hogg; Paul Lorigan; Celeste Lebbe; Thomas Jouary; Dirk Schadendorf; Antoni Ribas; Steven J O'Day; Jeffrey A Sosman; John M Kirkwood; Alexander M M Eggermont; Brigitte Dreno; Keith Nolop; Jiang Li; Betty Nelson; Jeannie Hou; Richard J Lee; Keith T Flaherty; Grant A McArthur
Journal:  N Engl J Med       Date:  2011-06-05       Impact factor: 91.245

3.  Glucose-activated RUNX2 phosphorylation promotes endothelial cell proliferation and an angiogenic phenotype.

Authors:  Adam D Pierce; Ian E Anglin; Michele I Vitolo; Maria T Mochin; Karen F Underwood; Simeon E Goldblum; Sravya Kommineni; Antonino Passaniti
Journal:  J Cell Biochem       Date:  2012-01       Impact factor: 4.429

4.  Regulation of RUNX2 transcription factor-DNA interactions and cell proliferation by vitamin D3 (cholecalciferol) prohormone activity.

Authors:  Karen F Underwood; David R D'Souza; Maria Mochin-Peters; Adam D Pierce; Sravya Kommineni; Moran Choe; Jessica Bennett; Averell Gnatt; Bahru Habtemariam; Alexander D MacKerell; Antonino Passaniti
Journal:  J Bone Miner Res       Date:  2012-04       Impact factor: 6.741

5.  Genomic promoter occupancy of runt-related transcription factor RUNX2 in Osteosarcoma cells identifies genes involved in cell adhesion and motility.

Authors:  Margaretha van der Deen; Jacqueline Akech; David Lapointe; Sneha Gupta; Daniel W Young; Martin A Montecino; Mario Galindo; Jane B Lian; Janet L Stein; Gary S Stein; Andre J van Wijnen
Journal:  J Biol Chem       Date:  2011-12-09       Impact factor: 5.157

6.  Reduced activity and cytoplasmic localization of Runx2 is observed in C3h10t1/2 cells overexpressing Tbx3.

Authors:  Vishwa Deepak; Zhongli Zhang; Lingyi Meng; Xianlu Zeng; Wenguang Liu
Journal:  Cell Biochem Funct       Date:  2011-06       Impact factor: 3.685

7.  Physical and functional interactions between Runx2 and HIF-1α induce vascular endothelial growth factor gene expression.

Authors:  Tae-Geon Kwon; Xiang Zhao; Qian Yang; Yan Li; Chunxi Ge; Guisheng Zhao; Renny T Franceschi
Journal:  J Cell Biochem       Date:  2011-12       Impact factor: 4.429

8.  RUNX3 interactome reveals novel centrosomal targeting of RUNX family of transcription factors.

Authors:  Linda Shyue Huey Chuang; Soak Kuan Lai; Maki Murata-Hori; Ayumi Yamada; Hoi-Yeung Li; Jayantha Gunaratne; Yoshiaki Ito
Journal:  Cell Cycle       Date:  2012-05-15       Impact factor: 4.534

9.  Runx2 protein stabilizes hypoxia-inducible factor-1α through competition with von Hippel-Lindau protein (pVHL) and stimulates angiogenesis in growth plate hypertrophic chondrocytes.

Authors:  Sun-Hee Lee; Xiangguo Che; Jae-Hwan Jeong; Je-Yong Choi; Young-Joo Lee; Yong-Hee Lee; Suk-Chul Bae; You-Mie Lee
Journal:  J Biol Chem       Date:  2012-02-20       Impact factor: 5.157

Review 10.  MDA-9/syntenin: a positive gatekeeper of melanoma metastasis.

Authors:  Swadesh K Das; Sujit K Bhutia; Timothy P Kegelman; Leyla Peachy; Regina A Oyesanya; Santanu Dasgupta; Upneet K Sokhi; Belal Azab; Rupesh Dash; Bridget A Quinn; Keetae Kim; Paola M Barral; Zhao-zhong Su; Habib Boukerche; Devanand Sarkar; Paul B Fisher
Journal:  Front Biosci (Landmark Ed)       Date:  2012-01-01
View more
  17 in total

1.  LncRNA E2F-Mediated Cell Proliferation Enhancing lncRNA Regulates Cancer Cell Behaviors and Affects Prognosis of Gastric Cancer.

Authors:  Jing Fu; Wenxing Zhao; Dongmei Guo; Zheng Li
Journal:  Dig Dis Sci       Date:  2019-10-04       Impact factor: 3.199

2.  The Thyroid Hormone Receptor-RUNX2 Axis: A Novel Tumor Suppressive Pathway in Breast Cancer.

Authors:  Eric L Bolf; Noelle E Gillis; Michael S Barnum; Caitlin M Beaudet; Grace Y Yu; Jennifer A Tomczak; Janet L Stein; Jane B Lian; Gary S Stein; Frances E Carr
Journal:  Horm Cancer       Date:  2019-12-21       Impact factor: 3.869

Review 3.  RUNX2 and the PI3K/AKT axis reciprocal activation as a driving force for tumor progression.

Authors:  Karine A Cohen-Solal; Rajeev K Boregowda; Ahmed Lasfar
Journal:  Mol Cancer       Date:  2015-07-25       Impact factor: 27.401

4.  Altered Transcriptional Control Networks with Trans-Differentiation of Isogenic Mutant-KRas NSCLC Models.

Authors:  John A Haley; Elizabeth Haughney; Erica Ullman; James Bean; John D Haley; Marc Y Fink
Journal:  Front Oncol       Date:  2014-12-08       Impact factor: 6.244

5.  The transcription factor RUNX2 regulates receptor tyrosine kinase expression in melanoma.

Authors:  Rajeev K Boregowda; Daniel J Medina; Elke Markert; Michael A Bryan; Wenjin Chen; Suzie Chen; Anna Rabkin; Michael J Vido; Samuel I Gunderson; Marina Chekmareva; David J Foran; Ahmed Lasfar; James S Goydos; Karine A Cohen-Solal
Journal:  Oncotarget       Date:  2016-05-17

6.  Down-regulated miR-23a Contributes to the Metastasis of Cutaneous Melanoma by Promoting Autophagy.

Authors:  Weinan Guo; Huina Wang; Yuqi Yang; Sen Guo; Weigang Zhang; Yu Liu; Xiuli Yi; Jingjing Ma; Tao Zhao; Lin Liu; Zhe Jian; Ling Liu; Gang Wang; Tianwen Gao; Qiong Shi; Chunying Li
Journal:  Theranostics       Date:  2017-06-01       Impact factor: 11.556

7.  The Expression and Functional Significance of Runx2 in Hepatocellular Carcinoma: Its Role in Vasculogenic Mimicry and Epithelial-Mesenchymal Transition.

Authors:  Zi Cao; Baocun Sun; Xiulan Zhao; Yanhui Zhang; Qiang Gu; Xiaohui Liang; Xueyi Dong; Nan Zhao
Journal:  Int J Mol Sci       Date:  2017-02-27       Impact factor: 5.923

8.  Dexamethasone and 1,25-dihydroxyvitamin D3 reduce oxidative stress-related DNA damage in differentiating osteoblasts.

Authors:  Elzbieta Pawlowska; Daniel Wysokiński; Paulina Tokarz; Agnieszka Piastowska-Ciesielska; Joanna Szczepanska; Janusz Blasiak
Journal:  Int J Mol Sci       Date:  2014-09-19       Impact factor: 5.923

9.  Nuclear HDAC6 inhibits invasion by suppressing NF-κB/MMP2 and is inversely correlated with metastasis of non-small cell lung cancer.

Authors:  Chih-Jen Yang; Yu-Peng Liu; Hong-Ying Dai; Yow-Ling Shiue; Chia-Jung Tsai; Ming-Shyan Huang; Yao-Tsung Yeh
Journal:  Oncotarget       Date:  2015-10-06

10.  Depletion of runt-related transcription factor 2 (RUNX2) enhances SAHA sensitivity of p53-mutated pancreatic cancer cells through the regulation of mutant p53 and TAp63.

Authors:  Takehiro Ogata; Mizuyo Nakamura; Meijie Sang; Hiroyuki Yoda; Kiriko Hiraoka; Danjing Yin; Mexiang Sang; Osamu Shimozato; Toshinori Ozaki
Journal:  PLoS One       Date:  2017-07-03       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.